<p>180 Wealth Advisors LLC 在第一季度增持了 MannKind Co.（NASDAQ:MNKD - Free Report）的股份，增幅為 12.6%，根據其最新提交給證券交易委員會的 13F 表格。該公司在本季度購入了額外的 216,880 股，持有這家生物製藥公司的 1,942,210 股股票。MannKind 佔 180 Wealth Advisors LLC 投資組合的約 1.6%，是其第 6 大持倉。根據最新提交給證券交易委員會的文件，180 Wealth Advisors LLC 持有的 MannKind 股份價值 8,798,000 美元，佔其投資組合的 0.72%。</p>
<p>許多其他機構投資者和對沖基金最近也買入和賣出了該公司的股票。Parkman Healthcare Partners LLC 在第 4 季度增持了 MannKind 的持股比例 20.8%。Parkman Healthcare Partners LLC 現在擁有 2,498,624 股這家生物製藥公司的股票，價值 9,095,000 美元，比上一季度增持了 429,677 股。Charles Schwab Investment Management Inc.在第 4 季度增持了 MannKind 的持股比例 1.5%。Charles Schwab Investment Management Inc.現在擁有 2,066,844 股這家生物製藥公司的股票，價值 7,523,000 美元，比上一季度增持了 30,433 股。Invesco Ltd.在第 3 季度增持了 MannKind 的持股比例 1.6%。Invesco Ltd.現在擁有 1,621,765 股這家生物製藥公司的股票，價值 6,698,000 美元，比上一季度增持了 25,319 股。Schonfeld Strategic Advisors LLC 在第 3 季度增持了 MannKind 的持股比例 10.1%。Schonfeld Strategic Advisors LLC 現在擁有 973,200 股這家生物製藥公司的股票，價值 4,019,000 美元，比上一季度增持了 89,005 股。最後，Connor Clark &amp; Lunn Investment Management Ltd.在第 3 季度增持了 MannKind 的持股比例 77.4%。Connor Clark &amp; Lunn Investment Management Ltd.現在擁有 740,078 股這家生物製藥公司的股票，價值 3,057,000 美元，比上一季度增持了 322,791 股。該股的 49.55% 由機構投資者和對沖基金持有。</p>
<h2>內部人士的買賣行為</h2>
<p>據相關消息，執行副總裁 David Thomson 於 5 月 21 日星期二進行了一筆交易，賣出了 23,537 股股票。該股票以每股平均價格 4.66 美元出售，總價值為 109,682.42 美元。交易完成後，該執行副總裁在公司中持有 873,616 股股票，價值 4,071,050.56 美元。該交易已在提交給證券交易委員會的文件中披露，可在此鏈接處查看。目前有 3.00% 的股份由公司內部人士持有。</p>
<h2>分析師設定新的價格目標</h2>
<p>MNKD 最近成為多份分析師報告的主題。Rodman &amp; Renshaw 在 6 月 13 日星期四的一份報告中開始對 MannKind 進行覆蓋。他們給予該股票一個&#34;買入&#34;評級，並設定了 8.00 美元的股價目標。Cantor Fitzgerald 在 5 月 9 日星期四重申了對 MannKind 的&#34;超重&#34;評級，並設定了 6.50 美元的股價目標。一位研究分析師給予該股票持有評級，另外四位分析師給予該公司買入評級。根據 MarketBeat 的數據，該股票的共識評級為&#34;中度買入&#34;，共識價格目標為 8.00 美元。</p>
<p><strong>查看我們對 MNKD 的最新分析</strong></p>
<h2>MannKind 股價下跌 1.5%</h2>
<p>MNKD 股票在週五交易時下跌了 0.08 美元，報 5.21 美元。該公司的股票在交易時段內交易量為 373,131 股，相比平均交易量 2,719,187 股。該公司的市值為 14.2 億美元，市盈率為 176.39，貝塔係數為 1.27。MannKind Co.的 52 周最低價為 3.17 美元，最高價為 5.75 美元。該公司的 50 天移動平均價格為 4.61 美元，200 天移動平均價格為 4.17 美元。</p>
<p>MannKind（NASDAQ:MNKD - Get Free Report）於 5 月 8 日星期三發佈了其財報。這家生物製藥公司在本季度每股盈利為 0.05 美元，超過分析師預期的 0.03 美元。該公司本季度的營收為 6626 萬美元，超過預期的 6055 萬美元。MannKind 的淨資產回報率為-3.35%，淨利潤率為 3.78%。該公司本季度的營收同比增長了 63.1%。在去年同期的同一季度，該公司每股虧損為（0.04）美元。作為一個整體，分析師預計 MannKind Co.在本財年將實現 0.1 美元的每股盈利。</p>
<h2>MannKind 簡介（免費報告）</h2>
<p>MannKind Corporation 是一家生物製藥公司，專注於開發和銷售用於美國內分泌和孤兒肺部疾病的吸入治療產品。公司提供 Afrezza，一種用於改善成年糖尿病患者血糖控制的吸入胰島素，以及 V-Go 可穿戴胰島素輸送裝置，為成年人提供持續皮下注射胰島素。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們喜歡的五隻股票，比 MannKind 更好</li>
<li>股市假期 2022-2025 年 - 紐約證券交易所和納斯達克將關閉的時間</li>
<li>Salesforce 股票：會議總結，人工智能重點和預測</li>
<li>突破性股票：它們是什麼以及如何識別它們</li>
<li>CAVA 是否過度擴張？對這隻高飛股票的更近一步瞭解</li>
<li>消費類必需品股票，解釋</li>
<li>Nike 股價在分析師下調目標後跌至低谷</li>
</ul>
<p><strong>想看看其他對沖基金持有 MNKD 的情況？</strong> 訪問 HoldingsChannel.com 獲取 MannKind Co.（NASDAQ:MNKD - Free Report）的最新 13F 提交和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經經過 MarketBeat 的編輯團隊審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 人工智能真正的下一步發展方向（來自 InvestorPlace）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2"/></p>
<h2>現在是否值得投資曼恩凱德生物醫療？</h2>
<p>在考慮曼恩凱德生物醫療之前，您需要聽到這個消息。</p>
<p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票...而曼恩凱德生物醫療不在這個列表上。</p>
<p>雖然曼恩凱德生物醫療目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

曼恩凱德生物醫療

<p>180 Wealth Advisors LLC 在第一季度增加了對 MannKind Co. (NASDAQ: MNKD) 的持股比例，根據其最新提交給證券交易委員會的文件，持股比例增加了 12.6%。該公司現在擁有該生物製藥公司的 1,942,210 股股份，使其成為他們的第 6 大持倉。MannKind 的股價目前為$5.21</p>

<p>180 Wealth Advisors LLC increased its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 12.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 1,942,210 shares of the biopharmaceutical company's stock after purchasing an additional 216,880 shares during the quarter. MannKind comprises about 1.6% of 180 Wealth Advisors LLC's portfolio, making the stock its 6th biggest holding. 180 Wealth Advisors LLC owned 0.72% of MannKind worth $8,798,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>180 Wealth Advisors LLC 在第一季度增持了 MannKind Co.（NASDAQ:MNKD - Free Report）的股份，增幅為 12.6%，根據其最新提交給證券交易委員會的 13F 表格。該公司在本季度購入了額外的 216,880 股，持有這家生物製藥公司的 1,942,210 股股票。MannKind 佔 180 Wealth Advisors LLC 投資組合的約 1.6%，是其第 6 大持倉。根據最新提交給證券交易委員會的文件，180 Wealth Advisors LLC 持有的 MannKind 股份價值 8,798,000 美元，佔其投資組合的 0.72%。</p>
</div><p>A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Parkman Healthcare Partners LLC lifted its holdings in MannKind by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 2,498,624 shares of the biopharmaceutical company's stock valued at $9,095,000 after acquiring an additional 429,677 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in MannKind by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,066,844 shares of the biopharmaceutical company's stock valued at $7,523,000 after acquiring an additional 30,433 shares during the last quarter. Invesco Ltd. lifted its holdings in MannKind by 1.6% in the 3rd quarter. Invesco Ltd. now owns 1,621,765 shares of the biopharmaceutical company's stock valued at $6,698,000 after acquiring an additional 25,319 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in MannKind by 10.1% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 973,200 shares of the biopharmaceutical company's stock worth $4,019,000 after buying an additional 89,005 shares during the period. Finally, Connor Clark &amp; Lunn Investment Management Ltd. raised its holdings in MannKind by 77.4% during the 3rd quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 740,078 shares of the biopharmaceutical company's stock worth $3,057,000 after buying an additional 322,791 shares during the period. 49.55% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>許多其他機構投資者和對沖基金最近也買入和賣出了該公司的股票。Parkman Healthcare Partners LLC 在第 4 季度增持了 MannKind 的持股比例 20.8%。Parkman Healthcare Partners LLC 現在擁有 2,498,624 股這家生物製藥公司的股票，價值 9,095,000 美元，比上一季度增持了 429,677 股。Charles Schwab Investment Management Inc.在第 4 季度增持了 MannKind 的持股比例 1.5%。Charles Schwab Investment Management Inc.現在擁有 2,066,844 股這家生物製藥公司的股票，價值 7,523,000 美元，比上一季度增持了 30,433 股。Invesco Ltd.在第 3 季度增持了 MannKind 的持股比例 1.6%。Invesco Ltd.現在擁有 1,621,765 股這家生物製藥公司的股票，價值 6,698,000 美元，比上一季度增持了 25,319 股。Schonfeld Strategic Advisors LLC 在第 3 季度增持了 MannKind 的持股比例 10.1%。Schonfeld Strategic Advisors LLC 現在擁有 973,200 股這家生物製藥公司的股票，價值 4,019,000 美元，比上一季度增持了 89,005 股。最後，Connor Clark &amp; Lunn Investment Management Ltd.在第 3 季度增持了 MannKind 的持股比例 77.4%。Connor Clark &amp; Lunn Investment Management Ltd.現在擁有 740,078 股這家生物製藥公司的股票，價值 3,057,000 美元，比上一季度增持了 322,791 股。該股的 49.55% 由機構投資者和對沖基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士的買賣行為</h2>
</div><p>In related news, EVP David Thomson sold 23,537 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $4.66, for a total value of $109,682.42. Following the transaction, the executive vice president now owns 873,616 shares in the company, valued at $4,071,050.56. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. 3.00% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>據相關消息，執行副總裁 David Thomson 於 5 月 21 日星期二進行了一筆交易，賣出了 23,537 股股票。該股票以每股平均價格 4.66 美元出售，總價值為 109,682.42 美元。交易完成後，該執行副總裁在公司中持有 873,616 股股票，價值 4,071,050.56 美元。該交易已在提交給證券交易委員會的文件中披露，可在此鏈接處查看。目前有 3.00% 的股份由公司內部人士持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>MNKD has been the topic of several recent analyst reports. Rodman &amp; Renshaw initiated coverage on MannKind in a report on Thursday, June 13th. They set a &#34;buy&#34; rating and a $8.00 price objective on the stock. Cantor Fitzgerald restated an &#34;overweight&#34; rating and set a $6.50 price objective on shares of MannKind in a report on Thursday, May 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $8.00.</p>
<div class="lb-trans"><p>MNKD 最近成為多份分析師報告的主題。Rodman &amp; Renshaw 在 6 月 13 日星期四的一份報告中開始對 MannKind 進行覆蓋。他們給予該股票一個&#34;買入&#34;評級，並設定了 8.00 美元的股價目標。Cantor Fitzgerald 在 5 月 9 日星期四重申了對 MannKind 的&#34;超重&#34;評級，並設定了 6.50 美元的股價目標。一位研究分析師給予該股票持有評級，另外四位分析師給予該公司買入評級。根據 MarketBeat 的數據，該股票的共識評級為&#34;中度買入&#34;，共識價格目標為 8.00 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on MNKD</strong></p>
<div class="lb-trans"><p><strong>查看我們對 MNKD 的最新分析</strong></p>
</div><h2>MannKind Stock Down 1.5 %</h2>
<div class="lb-trans"><h2>MannKind 股價下跌 1.5%</h2>
</div><p>Shares of MNKD traded down $0.08 during trading hours on Friday, reaching $5.21. The company's stock had a trading volume of 373,131 shares, compared to its average volume of 2,719,187. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 176.39 and a beta of 1.27. MannKind Co. has a 1-year low of $3.17 and a 1-year high of $5.75. The company has a 50 day moving average of $4.61 and a two-hundred day moving average of $4.17.</p>
<div class="lb-trans"><p>MNKD 股票在週五交易時下跌了 0.08 美元，報 5.21 美元。該公司的股票在交易時段內交易量為 373,131 股，相比平均交易量 2,719,187 股。該公司的市值為 14.2 億美元，市盈率為 176.39，貝塔係數為 1.27。MannKind Co.的 52 周最低價為 3.17 美元，最高價為 5.75 美元。該公司的 50 天移動平均價格為 4.61 美元，200 天移動平均價格為 4.17 美元。</p>
</div><p>MannKind (NASDAQ:MNKD - Get Free Report) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.02. The company had revenue of $66.26 million for the quarter, compared to the consensus estimate of $60.55 million. MannKind had a negative return on equity of 3.35% and a net margin of 3.78%. The firm's quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) EPS. As a group, analysts forecast that MannKind Co. will post 0.1 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MannKind（NASDAQ:MNKD - Get Free Report）於 5 月 8 日星期三發佈了其財報。這家生物製藥公司在本季度每股盈利為 0.05 美元，超過分析師預期的 0.03 美元。該公司本季度的營收為 6626 萬美元，超過預期的 6055 萬美元。MannKind 的淨資產回報率為-3.35%，淨利潤率為 3.78%。該公司本季度的營收同比增長了 63.1%。在去年同期的同一季度，該公司每股虧損為（0.04）美元。作為一個整體，分析師預計 MannKind Co.在本財年將實現 0.1 美元的每股盈利。</p>
</div><h2>MannKind Profile (Free Report)</h2>
<div class="lb-trans"><h2>MannKind 簡介（免費報告）</h2>
</div><p>MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.</p>
<div class="lb-trans"><p>MannKind Corporation 是一家生物製藥公司，專注於開發和銷售用於美國內分泌和孤兒肺部疾病的吸入治療產品。公司提供 Afrezza，一種用於改善成年糖尿病患者血糖控制的吸入胰島素，以及 V-Go 可穿戴胰島素輸送裝置，為成年人提供持續皮下注射胰島素。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than MannKind</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>Salesforce Stock: Meeting Recap, AI Focus, and Forecast</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Is CAVA Overextended? A Closer Look at This High-Flying Stock</li>
<li>Consumer Staples Stocks, Explained</li>
<li>Nike Stock Falls to Bargain Basement After Analysts Slash Targets</li>
</ul>
<div class="lb-trans"><h2>進一步閲讀</h2>
<ul>
<li>我們喜歡的五隻股票，比 MannKind 更好</li>
<li>股市假期 2022-2025 年 - 紐約證券交易所和納斯達克將關閉的時間</li>
<li>Salesforce 股票：會議總結，人工智能重點和預測</li>
<li>突破性股票：它們是什麼以及如何識別它們</li>
<li>CAVA 是否過度擴張？對這隻高飛股票的更近一步瞭解</li>
<li>消費類必需品股票，解釋</li>
<li>Nike 股價在分析師下調目標後跌至低谷</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding MNKD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MannKind Co. (NASDAQ:MNKD - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有 MNKD 的情況？</strong> 訪問 HoldingsChannel.com 獲取 MannKind Co.（NASDAQ:MNKD - Free Report）的最新 13F 提交和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MNKD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經經過 MarketBeat 的編輯團隊審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Where AI is REALLY Going Next (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 人工智能真正的下一步發展方向（來自 InvestorPlace）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8506&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in MannKind right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資曼恩凱德生物醫療？</h2>
</div><p>Before you consider MannKind, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮曼恩凱德生物醫療之前，您需要聽到這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票...而曼恩凱德生物醫療不在這個列表上。</p>
</div><p>While MannKind currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然曼恩凱德生物醫療目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

曼恩凱德生物醫療公司（NASDAQ:MNKD）的股份被 180 財富顧問公司收購